Premium
DUAL PI3K δ/γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL LYMPHOMA: DOSE ESCALATION FINDINGS.
Author(s) -
Oki Y.,
Zain J.,
Haverkos B.,
Barde P.,
Penmetsa K.,
Huen A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_191
Subject(s) - medicine , refractory (planetary science) , toxicity , gastroenterology , pharmacokinetics , pharmacodynamics , cohort , progressive disease , lymphoma , pharmacology , chemotherapy , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom